{"pmid":32416600,"title":"Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.","text":["Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.","The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been independently assessed. The aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene). We used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95 % limit of detection (LOD95). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n = 13) for a preliminary evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral infections (n = 6) and a panel of RNA from related human coronaviruses to evaluate assay specificity. PCR efficiency was >/=96 % for all assays and the estimated LOD95 varied within a 6-fold range. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene. We conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in patients by experienced molecular diagnostic laboratories.","J Clin Virol","van Kasteren, Puck B","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","de Jonge, Jorgen","van den Brandt, Annemarie","Molenkamp, Richard","Reusken, Chantal B E M","Meijer, Adam","32416600"],"abstract":["The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been independently assessed. The aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene). We used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95 % limit of detection (LOD95). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n = 13) for a preliminary evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral infections (n = 6) and a panel of RNA from related human coronaviruses to evaluate assay specificity. PCR efficiency was >/=96 % for all assays and the estimated LOD95 varied within a 6-fold range. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene. We conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in patients by experienced molecular diagnostic laboratories."],"journal":"J Clin Virol","authors":["van Kasteren, Puck B","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","de Jonge, Jorgen","van den Brandt, Annemarie","Molenkamp, Richard","Reusken, Chantal B E M","Meijer, Adam"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416600","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104412","keywords":["covid-19","coronavirus","in vitro diagnostics","rt-pcr","sars-cov-2","ncov-2019"],"topics":["Diagnosis"],"weight":1,"_version_":1666991242700914688,"score":9.490897,"similar":[{"pmid":32416598,"title":"SARS-CoV-2 detection by direct rRT-PCR without RNA extraction.","text":["SARS-CoV-2 detection by direct rRT-PCR without RNA extraction.","Rapid and reliable screening of SARS-CoV-2 is fundamental to assess viral spread and limit the pandemic we are facing. In this study, we compared direct rRT-PCR method (without RNA extraction) using SeeGene AllplexTM 2019-nCoV rRT-PCR with the RealStar(R) SARS-CoV-2 rRT-PCR kit (Altona Diagnostics). Furthermore, we assessed the impact of swab storage media composition on PCR efficiency. We show that SeeGene and Altona's assays provide similar efficiency. Importantly, we provide evidence that RNA extraction can be successfully bypassed when samples are stored in UTM medium or in molecular water but not when samples are stored in saline solution and in Hanks medium.","J Clin Virol","Merindol, Natacha","Pepin, Genevieve","Marchand, Caroline","Rheault, Marylene","Peterson, Christine","Poirier, Andre","Houle, Claudia","Germain, Hugo","Danylo, Alexis","32416598"],"abstract":["Rapid and reliable screening of SARS-CoV-2 is fundamental to assess viral spread and limit the pandemic we are facing. In this study, we compared direct rRT-PCR method (without RNA extraction) using SeeGene AllplexTM 2019-nCoV rRT-PCR with the RealStar(R) SARS-CoV-2 rRT-PCR kit (Altona Diagnostics). Furthermore, we assessed the impact of swab storage media composition on PCR efficiency. We show that SeeGene and Altona's assays provide similar efficiency. Importantly, we provide evidence that RNA extraction can be successfully bypassed when samples are stored in UTM medium or in molecular water but not when samples are stored in saline solution and in Hanks medium."],"journal":"J Clin Virol","authors":["Merindol, Natacha","Pepin, Genevieve","Marchand, Caroline","Rheault, Marylene","Peterson, Christine","Poirier, Andre","Houle, Claudia","Germain, Hugo","Danylo, Alexis"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416598","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104423","keywords":["covid19","coronavirus","direct rrtpcr","rna extraction","sars-cov-2","virus detection"],"topics":["Diagnosis"],"weight":1,"_version_":1666991242715594752,"score":292.15622},{"pmid":32350226,"title":"An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.","text":["An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.","The COVID-19 outbreak caused by SARS-CoV-2 in Wuhan (China) in December 2019 is currently spreading rapidly and globally. We recently reported a laboratory diagnostic protocol for SARS-CoV-2 based on real-time RT-PCR assays using two primer sets, N and N2. On 30-31 January 2020, the protocol and reagents for these assays were distributed to local public health institutes and quarantine depots in Japan, and nationwide, SARS-CoV-2 diagnostic testing was started. For further validation, the assays were compared with the commercially available kits using SARS CoV-2 viral RNA and the clinical specimens obtained from COVID19-suspected individuals. The LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E) assay was highly sensitive for SARS-CoV-2, as was the N2 set, and both assays had perfectly consistent results with the clinical specimens. While the LM S&W-E set targets the highly conserved region of the E gene in SARS-CoV and SARS-CoV-2, the N2 set was designed to target the unique region in the SARS-CoV-2 N gene. Thus, the N2 set has high specificity and sensitivity for SARS-CoV-2 detection. These indicate that the protocol using the N and N2 sets is comparable to commercially available kits and is reliable for the laboratory diagnosis of COVID-19.","Jpn J Infect Dis","Okamaoto, Kiyoko","Shirato, Kazuya","Nao, NagaNaganori","Saito, Shinji","Kageyama, Tsutomu","Hasegawa, Hideki","Suzuki, Tadaki","Matsuyama, Shutoku","Takeda, Makoto","32350226"],"abstract":["The COVID-19 outbreak caused by SARS-CoV-2 in Wuhan (China) in December 2019 is currently spreading rapidly and globally. We recently reported a laboratory diagnostic protocol for SARS-CoV-2 based on real-time RT-PCR assays using two primer sets, N and N2. On 30-31 January 2020, the protocol and reagents for these assays were distributed to local public health institutes and quarantine depots in Japan, and nationwide, SARS-CoV-2 diagnostic testing was started. For further validation, the assays were compared with the commercially available kits using SARS CoV-2 viral RNA and the clinical specimens obtained from COVID19-suspected individuals. The LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E) assay was highly sensitive for SARS-CoV-2, as was the N2 set, and both assays had perfectly consistent results with the clinical specimens. While the LM S&W-E set targets the highly conserved region of the E gene in SARS-CoV and SARS-CoV-2, the N2 set was designed to target the unique region in the SARS-CoV-2 N gene. Thus, the N2 set has high specificity and sensitivity for SARS-CoV-2 detection. These indicate that the protocol using the N and N2 sets is comparable to commercially available kits and is reliable for the laboratory diagnosis of COVID-19."],"journal":"Jpn J Infect Dis","authors":["Okamaoto, Kiyoko","Shirato, Kazuya","Nao, NagaNaganori","Saito, Shinji","Kageyama, Tsutomu","Hasegawa, Hideki","Suzuki, Tadaki","Matsuyama, Shutoku","Takeda, Makoto"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350226","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7883/yoken.JJID.2020.108","keywords":["covid-19","sars-cov-2","real-time rt-pcr"],"locations":["Wuhan","China","Japan"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495593218048,"score":253.20786},{"pmid":32391662,"title":"[Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection].","text":["[Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection].","OBJECTIVE: To compare the diagnostic efficacy among three RT-PCR test kits for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid detection. METHODS: The throat swab samples from 40 hospitalized patients clinically diagnosed as coronavirus disease 2019 (COVID-19) and 16 hospitalized non-COVID-19 patients were recruited. The SARS-CoV-2 nucleic acid was detected in throat swab samples with RT-PCR test kits from Sansure Biotech (\"Sansure\" for short), Jiangsu Bioperfectus Technologies (\"Bioperfectus\" for short) and BGI Genomics (\"BGI\" for short). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and Kappa value were analyzed. The viral nucleic acid was extracted from the throat swab samples by one-step cleavage and magnetic bead methods, and the efficacy of two extraction methods was also compared. The results of magnetic bead method for nucleic acid extraction by two different extractors (Sansure Natch CS S12C Fully Automated Nucleic Acid Extraction System vs. Tianlong NP968-C Nucleic Acid Extractor) were also compared. RESULTS: The sensitivity, specificity, PPV, NPV and kappa value were 95.00%, 87.50%, 95.00%, 87.50%and 0.825 for Sansure kit; 90.00%, 87.50%, 94.74%, 77.78%and 0.747 for the Bioperfectus kit, and 82.50%, 81.25%, 91.67%, 65.00%and 0.593 for the BGI kit, respectively. The positive, negative and total coincident rates and kappa value of viral nucleic acid detection results using the samples extracted by one-step cleavage and magnetic bead methods were 95.24%, 100.00%, 96.43%and 0.909, respectively, but the one-step cleavage method took only 25 min, while the magnetic bead method required 180 min. The positive, negative and total coincident rates and kappa value of viral nucleic acid detection results using the samples extracted by the two different nucleic acid extractors were 85.00%, 100.00%, 89.29% and 0.764, respectively. CONCLUSIONS: The detection efficacy for SARS-CoV-2 nucleic acid by the Sansure kit is relatively higher and the one-step cleavage method has advantages of convenient operation and less time consuming.","Zhejiang Da Xue Xue Bao Yi Xue Ban","Shen, Lihua","Huang, Fei","Chen, Xiang","Xiong, Zuan","Yang, Xiaoyu","Li, Hui","Cheng, Feng","Guo, Jian","Gong, Guofu","32391662"],"abstract":["OBJECTIVE: To compare the diagnostic efficacy among three RT-PCR test kits for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid detection. METHODS: The throat swab samples from 40 hospitalized patients clinically diagnosed as coronavirus disease 2019 (COVID-19) and 16 hospitalized non-COVID-19 patients were recruited. The SARS-CoV-2 nucleic acid was detected in throat swab samples with RT-PCR test kits from Sansure Biotech (\"Sansure\" for short), Jiangsu Bioperfectus Technologies (\"Bioperfectus\" for short) and BGI Genomics (\"BGI\" for short). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and Kappa value were analyzed. The viral nucleic acid was extracted from the throat swab samples by one-step cleavage and magnetic bead methods, and the efficacy of two extraction methods was also compared. The results of magnetic bead method for nucleic acid extraction by two different extractors (Sansure Natch CS S12C Fully Automated Nucleic Acid Extraction System vs. Tianlong NP968-C Nucleic Acid Extractor) were also compared. RESULTS: The sensitivity, specificity, PPV, NPV and kappa value were 95.00%, 87.50%, 95.00%, 87.50%and 0.825 for Sansure kit; 90.00%, 87.50%, 94.74%, 77.78%and 0.747 for the Bioperfectus kit, and 82.50%, 81.25%, 91.67%, 65.00%and 0.593 for the BGI kit, respectively. The positive, negative and total coincident rates and kappa value of viral nucleic acid detection results using the samples extracted by one-step cleavage and magnetic bead methods were 95.24%, 100.00%, 96.43%and 0.909, respectively, but the one-step cleavage method took only 25 min, while the magnetic bead method required 180 min. The positive, negative and total coincident rates and kappa value of viral nucleic acid detection results using the samples extracted by the two different nucleic acid extractors were 85.00%, 100.00%, 89.29% and 0.764, respectively. CONCLUSIONS: The detection efficacy for SARS-CoV-2 nucleic acid by the Sansure kit is relatively higher and the one-step cleavage method has advantages of convenient operation and less time consuming."],"journal":"Zhejiang Da Xue Xue Bao Yi Xue Ban","authors":["Shen, Lihua","Huang, Fei","Chen, Xiang","Xiong, Zuan","Yang, Xiaoyu","Li, Hui","Cheng, Feng","Guo, Jian","Gong, Guofu"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391662","source":"PubMed","week":"202020|May 11 - May 17","locations":["kappa","kappa"],"topics":["Diagnosis"],"weight":1,"_version_":1666528580133191681,"score":247.54086},{"pmid":32501535,"title":"Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","text":["Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved.","J Med Virol","Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang","32501535"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501535","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26140","keywords":["covid-19","rt-pcr","sars-cov-2","diagnosis","nanopore sequencing","nsp1"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1668890966407249920,"score":243.9947},{"pmid":32422410,"title":"A multiple center clinical evaluation of an ultra-fast single-tube assay for SARS-CoV-2 RNA.","text":["A multiple center clinical evaluation of an ultra-fast single-tube assay for SARS-CoV-2 RNA.","OBJECTIVES: To evaluate the performance of an ultra-fast single-tube nucleic acid isothermal amplification detection assay for SARS-CoV-2 RNA using clinical samples from multiple centers. METHODS: A reverse transcription recombinase-aided amplification (RT-RAA) assay for SARS-CoV-2 was conducted within 15minutesat39 degrees C with portable instruments after addition of extracted RNA. The clinical performance of RT-RAA assay was evaluated using 947 clinical samples from five institutions in four regions of China, and the approved commercial real-time fluorescent RT-PCR (qRT-PCR) kits were used for parallel detection. The sensitivity and specificity of RT-RAA were compared and analyzed. RESULTS: The RT-RAA test results of 926 samples were consistent with those of qRT-PCR (330 were positive, 596 were negative) and 21 were inconsistent. The sensitivity and specificity of RT-RAA was 97.63% [330/338, 95% confidence interval (CI): 95.21 to 98.90] and 97.87% (596/609, 95% CI: 96.28 to 98.81), respectively. The positive predictive value (PPV) and negative predictive value (NPV) were 96.21% (330/343, 95% CI: 93.45 to 97.88), and 98.68% (596/604, 95% CI: 97.30 to 99.38), respectively. The total coincidence rate was 97.78% (926/947, 95% CI: 96.80 to 98.70) and the Kappa was 0.952 (P <0.05). CONCLUSION: With comparable sensitivity and specificity to the commercial qRT-PCR kits, RT-RAA assay for SARS-CoV-2 exhibited distinctive advantages of simplicity and rapidity in terms of operation and turn-around time.","Clin Microbiol Infect","Wang, Ji","Cai, Kun","He, Xiaozhou","Shen, Xinxin","Wang, Jinrong","Liu, Jun","Xu, Junqiang","Qiu, Feng","Lei, Wenwen","Cui, Lunbiao","Ge, Yiyue","Wu, Tao","Zhang, Yanjun","Yan, Hao","Chen, Yin","Yu, Jiezhong","Ma, Xiaojun","Shi, Hua","Zhang, Ruiqing","Li, Xinna","Gao, Yuan","Niu, Peihua","Tan, Wenjie","Wu, Guizhen","Jiang, Yongzhong","Xu, Wenbo","Ma, Xuejun","32422410"],"abstract":["OBJECTIVES: To evaluate the performance of an ultra-fast single-tube nucleic acid isothermal amplification detection assay for SARS-CoV-2 RNA using clinical samples from multiple centers. METHODS: A reverse transcription recombinase-aided amplification (RT-RAA) assay for SARS-CoV-2 was conducted within 15minutesat39 degrees C with portable instruments after addition of extracted RNA. The clinical performance of RT-RAA assay was evaluated using 947 clinical samples from five institutions in four regions of China, and the approved commercial real-time fluorescent RT-PCR (qRT-PCR) kits were used for parallel detection. The sensitivity and specificity of RT-RAA were compared and analyzed. RESULTS: The RT-RAA test results of 926 samples were consistent with those of qRT-PCR (330 were positive, 596 were negative) and 21 were inconsistent. The sensitivity and specificity of RT-RAA was 97.63% [330/338, 95% confidence interval (CI): 95.21 to 98.90] and 97.87% (596/609, 95% CI: 96.28 to 98.81), respectively. The positive predictive value (PPV) and negative predictive value (NPV) were 96.21% (330/343, 95% CI: 93.45 to 97.88), and 98.68% (596/604, 95% CI: 97.30 to 99.38), respectively. The total coincidence rate was 97.78% (926/947, 95% CI: 96.80 to 98.70) and the Kappa was 0.952 (P <0.05). CONCLUSION: With comparable sensitivity and specificity to the commercial qRT-PCR kits, RT-RAA assay for SARS-CoV-2 exhibited distinctive advantages of simplicity and rapidity in terms of operation and turn-around time."],"journal":"Clin Microbiol Infect","authors":["Wang, Ji","Cai, Kun","He, Xiaozhou","Shen, Xinxin","Wang, Jinrong","Liu, Jun","Xu, Junqiang","Qiu, Feng","Lei, Wenwen","Cui, Lunbiao","Ge, Yiyue","Wu, Tao","Zhang, Yanjun","Yan, Hao","Chen, Yin","Yu, Jiezhong","Ma, Xiaojun","Shi, Hua","Zhang, Ruiqing","Li, Xinna","Gao, Yuan","Niu, Peihua","Tan, Wenjie","Wu, Guizhen","Jiang, Yongzhong","Xu, Wenbo","Ma, Xuejun"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422410","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cmi.2020.05.007","keywords":["covid-19","rt-raa","sars-cov-2","detection","multicenter evaluation"],"locations":["China","Kappa"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1667159284602896385,"score":230.54138}]}